phospho-valproic acid

**Phospho-valproic acid** is a **novel derivative of valproic acid** chemically modified with a phosphate group. It was developed as a potential anticancer agent, particularly targeting pancreatic cancer. Its mechanism centers on **potent inhibition of signal transducer and activator of transcription 3 (STAT3)**. Phospho-valproic acid prevents STAT3 phosphorylation, disrupts the Hsp90-STAT3 association, reduces STAT3 mitochondrial translocation, increases mitochondrial reactive oxygen species, and induces apoptosis. In preclinical studies, it suppressed pancreatic cancer growth in mouse xenograft models, and its efficacy was further increased when formulated in poly-(L)-lactic acid-poly(ethylene glycol) (PLLA-PEG) nanoparticles, which enhance pharmacokinetics and bioavailability[2][3][5].

Other names

phospho-valproic acidP-VMDC-1112MDC1112MDC 1112